Verona Pharma Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Verona Pharma Plc (VRNA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Verona Pharma Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 222M vs 164,916M combined for tracked competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+86.1% annualized vs trailing 12 months), vs decelerating (-21.0%) for its tracked peer group.
- Profitability: Its 11.6% net margin compares with 18.9% for the peer group.
- Peer revenue share: Verona Pharma Plc accounted for 0.3% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $2.81M compares with $0.85M for the peer group (3.3x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
VRNA Sales vs. its Competitors, Q2 2025
With a net margin of 11.56 %, Verona Pharma Plc reported lower profitability than its competitors (18.88 %).
Verona Pharma Plc generated 0.32 % of the combined sales of its peer group.
Verona Pharma Plc vs. its Competitors, Q2 2025
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Verona Pharma Plc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Verona Pharma Plc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (3) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Verona Pharma Plc's competitor groups requires a Commercial License.
Verona Pharma Plc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Verona Pharma Plc | No | - | - | No |
| Competitors combined (23) | ||||
| High-Confidence Competitors (3) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
VRNA Stock Performance relative to its Competitors
VRNA Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Edgewise Therapeutics inc | 282.9% | Outperformed |
| 2 | Intra cellular Therapies Inc | 282.9% | Outperformed |
| 3 | Viatris Inc | 282.9% | Outperformed |
| 4 | Nuvation Bio Inc | 282.9% | Outperformed |
| 5 | Zymeworks Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Verona Pharma Plc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Verona Pharma Plc's Comment on Competition and Industry Peers
Publicly Traded Peers of Verona Pharma Plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Verona Pharma Plc | 9,718.43 | 221.67 |
| Novartis Ag | 287,150.40 | 56,674.00 |
| Astrazeneca Plc | 259,526.30 | 58,739.00 |
| Gsk Plc | 102,307.45 | 32,667.00 |
| Viatris Inc | 21,253.49 | 14,737.30 |
| Intra cellular Therapies Inc | 13,599.88 | 680.85 |
| SUBTOTAL | 714,919.02 | 166,462.48 |
Sign in to see all competitors of Verona Pharma Plc.
Sources: Verona Pharma Plc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Verona Pharma Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Verona Pharma Plc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| GlaxoSmithKline | Named by the company | 85% |
| AstraZeneca plc | Named by the company | 85% |
| Novartis International AG | Named by the company | 85% |
| Boehringer Ingelheim GmbH | Named by the company | 85% |
| Viatris Inc | Named by the company | 85% |
| Vertex Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Verona Pharma Plc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Verona Pharma Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Viatris Inc | Developed Markets 57.61 % |
| Blueprint Medicines Corporation | Single Reportable Segment 100.00 % |
| Amphastar Pharmaceuticals Inc | Pharmaceutical products segment 100.00 % |
| Phathom Pharmaceuticals Inc | Reportable Segment Aggregation Before Other Operating Segment 100.00 % |
| Mersana Therapeutics inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Verona Pharma Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Verona Pharma Plc | 9,718 | 2,805,987 | -1,027,684 |
| Novartis Ag | 287,150 | 752,973 | 185,566 |
| Astrazeneca Plc | 259,526 | 706,847 | 123,141 |
| Gsk Plc | 102,307 | 128,610,236 | 24,759,843 |
| Viatris Inc | 21,253 | 491,243 | -13,690 |
| Intra cellular Therapies Inc | 13,600 | 3,370,554 | -369,683 |
| PEERS TOTAL | 705,201 | 851,242 | 145,371 |
Verona Pharma Plc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Nuvation Bio Inc | US 92.98 % |
| Amphastar Pharmaceuticals Inc | US 92.91 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Verona Pharma Plc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Verona Pharma Plc's industry classification, broader than the peer set above. Market cap in millions of $.Verona Pharma Plc ranks #0 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 827, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,062,533 | 19.39 % |
| 2 | Johnson and Johnson | 664,610 | 12.13 % |
| 3 | Beone Medicines Ltd | 545,679 | 9.96 % |
| 4 | Abbvie Inc | 467,633 | 8.54 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Verona Pharma Plc | 77,747 | 0.00 % |
Market cap and industry share for the rest of Verona Pharma Plc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-10-06.
Verona Pharma Plc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 100.00 % | 64.89 % (avg) | +35.1 pp |
| Operating Margin | -25.27 % | industry median | +32.5 pp |
| EBITDA Margin | -20.80 % | -7.21 % (avg) | -13.6 pp |
| Capital Intensity (Capex / Revenue) | 0.00 % | 4.92 % (avg) | -4.9 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Verona Pharma Plc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | 38.2x | 4.5x | +33.7x |
| Return on Equity | -38.66 % | industry aggregate | -57.55 % |
| Return on Invested Capital | -8.17 % | -2.95 % (avg) | -5.22 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Verona Pharma Plc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Operating Margin | - | - | - | - | - |
| Return on Invested Capital | - | -22.43 % | -21.10 % | -11.81 % | -27.36 % |
| P/E | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Verona Pharma Plc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 827 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 4.92 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Verona Pharma Plc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Verona Pharma Plc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Verona Pharma Plc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Verona Pharma Plc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Verona Pharma Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 32.5 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+86.1% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 57.6 points below the industry aggregate.
Opportunities
- A meaningful share of tracked competitors (45.50 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-21.0% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Verona Pharma Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Verona Pharma Plc | 8.83 | 10.47 | 0.86 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Gsk Plc | - | - | - |
| Viatris Inc | 0.18 | 1.47 | 0.96 |
| Intra cellular Therapies Inc | 2.40 | 6.78 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Verona Pharma Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Verona Pharma Plc | Q2 2025 | - | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Gsk Plc | Q4 2025 | +4.1 % | +113.1 % |
| Viatris Inc | Q2 2026 | +4.9 % | - |
| Intra cellular Therapies Inc | Q4 2024 | +50.8 % | - |
| PEERS TOTAL | +8.0 % | +38.5 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Verona Pharma Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Verona Pharma Plc | Q2 2025 | - | - |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Gsk Plc | Q4 2025 | +2.9 % | -0.6 % |
| Viatris Inc | Q2 2026 | +2.3 % | -0.2 % |
| Intra cellular Therapies Inc | Q4 2024 | - | - |
Verona Pharma Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Verona Pharma Plc | - | - | - |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Gsk Plc | 10.29% | 51.22% | 39.41% |
| Viatris Inc | - | - | - |
| Intra cellular Therapies Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Verona Pharma Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Verona Pharma Plc | - | 43.84 |
| Novartis Ag | 20.53 | 5.07 |
| Astrazeneca Plc | 25.38 | 4.42 |
| Gsk Plc | 17.90 | 3.13 |
| Viatris Inc | - | 1.44 |
| Intra cellular Therapies Inc | - | 19.97 |
| PEERS AVERAGE | 25.25 | 4.29 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.